ADXN — Addex Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1574232 ·
Last close
$5.20
Market Cap
$6.58M
52W High
$7.35
52W Low
$5.04
ADV30
2,297
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -479,827 | -1,711,739 | 4,759,193 | 935,153 | 1,472,531 |
| Dec 2025 | 248 | — | -779,263 | -1,836,987 | 6,364,272 | 1,638,612 | 1,597,580 |
| Sep 2025 | 29,724 | — | -696,175 | -1,577,231 | 7,330,802 | 2,187,202 | 1,372,247 |
| Jun 2025 | 0 | — | -732,898 | -1,841,165 | 8,506,015 | 2,300,994 | 1,293,289 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,575,307
Investing CF
$38,329
Financing CF
$1,106,473
CapEx
—
Dividends Paid
$0
Buybacks
$-2,746
EPS Diluted TTM
$-7.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-358,253,714
Inventory
—
Receivables
$51,247
ST Investments
$6,860
EBIT TTM
$-6,195,502
Pretax Income TTM
$-6,198,837
Interest Exp TTM
$3,335
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$109,496
EBITDA
$-2,689,751
Free Cash Flow
$-1,524,704
Enterprise Value
$4,337,601
Total Cash
$935,153
Total Debt
$102,269
Shares Out
1,265,844
Trailing EPS
$-8.85
Book Value
$4.12
ROE
-122.3%
ROA
-23.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 29,972 | -2,814,598 | -6,728,246 | 6,364,272 | 1,597,580 | — | -2,171,117 |
| Dec 2024 | 404,102 | -2,755,233 | 7,055,787 | 10,678,303 | 1,001,032 | — | -5,373,554 |
| Dec 2023 | 1,612,953 | -2,242,967 | -10,556,227 | 4,641,885 | 3,496,420 | — | -7,992,411 |
| Dec 2022 | 1,422,438 | -10,540,901 | -20,804,213 | 8,282,050 | 3,369,139 | — | -16,437,185 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KAPA | Kairos Pharma, LTD. | $6.55M | $0.31 | — |
| IMNN | Imunon, Inc. | $6.68M | $1.59 | — |
| CANF | Can-Fite BioPharma Ltd. | $6.75M | $3.15 | — |
| PULM | Pulmatrix, Inc. | $6.35M | $1.74 | — |
| ENVB | Enveric Biosciences, Inc. | $6.32M | $1.57 | — |
News headlines (Yahoo Finance, 1h cache)
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
2026-07-08 05:00 · Yahoo
Addex Shareholders Approve All Resolutions at Annual General Meeting
2026-06-30 05:00 · Yahoo
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
2026-06-25 21:00 · Yahoo
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-06-25 05:00 · Yahoo
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
2026-06-22 05:00 · Yahoo
Addex Convenes Annual General Meeting 2026
2026-06-05 05:00 · Yahoo
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
2026-04-30 05:00 · Yahoo
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
2026-04-29 05:00 · Yahoo
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
2026-04-23 05:00 · Yahoo
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
2026-04-21 05:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.